Literature DB >> 9164591

Effects of d-amphetamine in grouped versus isolated humans.

H de Wit1, M Clark, L H Brauer.   

Abstract

This study was designed to determine whether the subjective, behavioral or physiological effects of a stimulant drug in humans depend on whether subjects are tested under isolated or social conditions. Forty-two subjects were randomly assigned to either the Social (SOC) or Isolated (ISO) condition. SOC subjects participated in 4 h laboratory sessions in groups of 3 or 4, whereas ISO subjects participated in the sessions alone. All subjects participated in three sessions, during which they received capsules containing d-amphetamine (10 or 20 mg) or placebo, in mixed order under double blind conditions. Subjective, physiological and behavioral measures were obtained at regular intervals, d-amphetamine produced dose-related, prototypic stimulant effects on many measures, including self-reported mood states, behavioral indices and physiological measures. Most of these effects were unaffected by the setting in which subjects were tested (SOC vs ISO). However, body temperature was overall higher in the SOC group, and there was a trend for d-amphetamine to produce greater hyperthermic effects in the SOC group. In addition, 10 mg d-amphetamine increased heart rate in the SOC group but not in the ISO group. The results suggest that, like in laboratory animals, some of the effects of stimulants in humans are greater under aggregated conditions. However, unlike in the animal studies, this observed enhancement of the drug's effects under aggregated conditions was limited to physiological measures and did not apply to other subjective or behavioral measures.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9164591     DOI: 10.1016/s0091-3057(96)00316-4

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  9 in total

1.  MDMA effects consistent across laboratories.

Authors:  Matthew G Kirkpatrick; Matthew J Baggott; John E Mendelson; Gantt P Galloway; Matthias E Liechti; Cédric M Hysek; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2014-03-15       Impact factor: 4.530

2.  Relationship between drug discrimination and ratings of subjective effects: implications for assessing and understanding the abuse potential of D-amphetamine in humans.

Authors:  Anna R Reynolds; B Levi Bolin; William W Stoops; Craig R Rush
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

3.  Amphetamine as a social drug: effects of d-amphetamine on social processing and behavior.

Authors:  Margaret C Wardle; Matthew J Garner; Marcus R Munafò; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2012-04-13       Impact factor: 4.530

4.  In the company of others: social factors alter acute alcohol effects.

Authors:  Matthew G Kirkpatrick; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2013-05-28       Impact factor: 4.530

5.  Methamphetamine and core temperature in the rat: ambient temperature, dose, and the effect of a D2 receptor blocker.

Authors:  Karen E Sabol; Danielle M Yancey; H Anton Speaker; Scott L Mitchell
Journal:  Psychopharmacology (Berl)       Date:  2013-06-04       Impact factor: 4.530

6.  MDMA: a social drug in a social context.

Authors:  Matthew G Kirkpatrick; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2014-10-05       Impact factor: 4.530

Review 7.  Considering the context: social factors in responses to drugs in humans.

Authors:  Harriet de Wit; Michael Sayette
Journal:  Psychopharmacology (Berl)       Date:  2018-02-22       Impact factor: 4.530

Review 8.  Sympathomimetic amine compounds and hepatotoxicity: Not all are alike-Key distinctions noted in a short review.

Authors:  Cyril Willson
Journal:  Toxicol Rep       Date:  2018-12-01

Review 9.  The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?

Authors:  Anya K Bershad; Melissa A Miller; Matthew J Baggott; Harriet de Wit
Journal:  J Psychopharmacol       Date:  2016-08-25       Impact factor: 4.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.